drugset
drugset / Trial / NCT05186545

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

NCT05186545 ↗

Phase 2 Unknown 63 enrolled The First Affiliated Hospital of Zhengzhou University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single center, single arm phase II study designed to explore the efficacy and safety of surufatinib + fulvastrant + chidamide combinational treatment in HR positive breast cancer refractory to endocrine therapy.

Timeline

Start
2022-07-01
Primary completion
2024-01
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulvestrant Small molecule 500 mg Intramuscular
Subject Surufatinib Small molecule 250 mg Oral
Subject Tucidinostat Small molecule 30 mg Oral

Indications

female breast carcinoma